A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation

Neurogastroenterology and Motility

Volumn 22, Issue 9, 2010, Pages

  Muller Lissner S ^a   Rykx, A ^b   Kerstens, R ^b   Vandeplassche, L ^b  

^a Park Klinik Weissensee   (Germany)

^b Movetis NV   (Belgium)

Author keywords

5 HT4 receptors; colon motility; consti pation; elderly; enterokinetic; prucalopride

Indexed keywords

PLACEBO; PRUCALOPRIDE;

AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BENZOFURANS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CONSTIPATION; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77955493094     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2010.01533.x     Document Type: Article

References (35)

1. Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003 98 : 1107 1111.
2. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol 2008 8 : 5.
3. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004 99 : 750 759.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 1491.
5. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci 1995 50 : M184 9.
6. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004 20 : 31 9.
7. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997 32 : 1083 1089.
8. Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. J Am Geriatr Soc 1993 41 : 1130 1140.
9. Camilleri M, Cowen T, Koch TR. Enteric neurodegeneration in ageing. Neurogastroenterol Motil 2008 20 : 418 429.
10. Bosshard W, Dreher R, Schnegg J, Bula C. The treatment of chronic constipation in elderly people: an update. Drugs Aging 2004 21 : 911 930.
11. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005 100 : 232 242.
12. Darlington R. OTC laxatives. J Am Pharm Assoc 1966 6 : 470 474.
13. Voskuijl W, de Lorijn F, Verwijs W et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004 53 : 1590 1594.
14. Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum 2000 43 : 940 943.
15. Bassotti G, Gaburri M, Imbimbo BP et al. Colonic mass movements in idiopathic chronic constipation. Gut 1988 29 : 1173 1179.
16. Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995 47 : 631 651.
17. Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006 24 : 59 69.
18. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. J Pharmacol Exp Ther 2001 299 : 1007 1012.
19. Busti AJ, Murillo JR Jr., Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004 24 : 526 531.
20. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 358 : 2344 2354.
21. Camilleri M, Specht Gryp R, Kerstens R, Vanderplassche L. Efficacy of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three identical randomized, double-blind, placebo controlled phase III trials. Gastroenterology 2008 134 : A-548.
22. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 29 : 315 328.
23. Tack J, Ausma J, Kerstens R, Vanderplassche L. Safety and tolerability of prucalopride (Resolor) in patients with chronic constipation: pooled data from three pivotal phase III studies. Gastroenterology 2008 134 : A-530.
24. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 58 : 357 365.
25. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001 13 : 465 472.
26. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005 40 : 540 551. (Pubitemid 40676247)
27. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999 34 : 870 877.
28. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 1666.
29. Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S. Constipation: a different entity for patients and doctors. Fam Pract 1996 13 : 156 159.
30. Van de Velde V, Ausma J, Vandeplassche L Pharmacokinetics of prucalopride (Resolor) in man [Abstract P0891]. Gut 2008 57 : A282.
31. Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001 10 : 268 273.
32. Dupont C, Leluyer B, Maamri N et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005 41 : 625 633.
33. Pare P, Ferrazzi S, Thompson W, Irvine E, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 96 : 3130 3137.
34. 4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008 20 : 99 112.
35. Briejer MR, Bosmans JP, Van Daele P et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001 423 : 71 83.